tbuckley/cabot-search huggingface dataset:
A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1
Authors: Kwong-Yok Tsang, Claudia Palena, James Gulley, Philip Arlen, Jeffrey Schlom
Journal: Clinical Cancer Research (2004)

MUC-1/DF-3 remains an attractive target for vaccine therapy. It is overexpressed in the majority of human carcinomas and multiple myeloma. Clinical trials using MUC-1-based vaccines have demonstrated safety, clinical responses, and the induction of T-cell responses directed against MUC-1. Previous studies in experimental models and in clinical trials have demonstrated that altering the amino acid sequence of a "self" epitope can lead to the generation of an enhancer agonist epitope capable of eliciting stronger T-cell responses than the native epitope can.We describe here the identification of six novel class I HLA-A2 epitopes of MUC-1 that reside outside of the variable number of tandem repeat region. Each is shown to have the ability to activate human T cells as measured by IFN-gamma production. One epitope (ATWGQDVTSV, at amino acid position 92-101 and designated P-92), which demonstrated the highest level of binding to HLA-A2 and which induced the highest level of IFN-gamma in human T cells, was further studied for the generation of potential enhancer agonist epitopes. Of four potential agonists identified, one epitope (ALWGQDVTSV, designated P-93L) was identified as an enhancer agonist. Compared with the native P-92 peptide, the P-93L agonist (a). bound HLA-A2 at lower peptide concentrations, (b). demonstrated a higher avidity for HLA-A2 in dissociation assays, (c). when used with antigen-presenting cells, induced the production of more IFN-gamma by T cells than with the use of the native peptide, and (d). was capable of more efficiently generating MUC-1-specific human T-cell lines from normal volunteers and pancreatic cancer patients. Most importantly, the T-cell lines generated using the agonist epitope were more efficient than those generated with the native epitope in the lysis of targets pulsed with the native epitope and in the lysis of HLA-A2 human tumor cells expressing MUC-1.In addition to the identification of novel MUC-1 epitopes outside the variable number of tandem repeat region, the studies reported here describe the first agonist epitope of MUC-1. The employment of this agonist epitope in peptide-, protein-, and vector-based vaccines may well aid in the development of effective vaccines for a range of human cancers.
Super-sleuthing with the CDC's Epidemiologic Intelligence Service
Authors: P. Gunby
Journal: JAMA (1979)

Forty-six physicians, two veterinarians, a doctor of pharmacy, and an anthropologist report July 5 to the Center for Disease Control (CDC) on Atlanta's outskirts to begin a series of experiences in epidemiology that will continue anywhere from two years to a lifetime. These six women and 44 men make up the 29th entering class of the Epidemic Intelligence Service (EIS), a medical sleuthing organization that got its name (and a reason for its creation) from concern in the 1950s over possible biological warfare. An expanding, changing world of medical epidemiology awaits them. As James Chin, MD, California Department of Health Services, points out, "Until the last decade, most medical epidemiology by public health agencies focused on acute, infectious disease problems. Now, these efforts in many areas are expanding into long-term, chronic health problems— the kinds that long have been studied by university schools of public health." Further, says Ronald Altman,
October 3, 2001
Journal: JAMA (2001)

Debra A. Guinn, MD; M. Wendy Atkinson, MD; Lisa Sullivan, PhD; MenJean Lee, MD; Scott MacGregor, DO; Barbara V. Parilla, MD; Jill Davies, MD; Kathleen Hanlon-Lundberg, MD; Lynn Simpson, MD; Joanne Stone, MD; Deborah Wing, MD; Keith Ogasawara, MD; Jonathan Muraskas, MD
Poliomyelitis: A Survey Made Possible by a Grant From the International Committee for the Study of Infantile Paralysis.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Pediatrics
Authors: Phil Fontanarosa, Annette Flanagin, Paula Glitman, Lauren Fischer, John Mcfadden, Donald Smith, Karen Boyd, Rochelle Lodder, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamcyzk, Jan Alden, Mary Clavey, Gillian Coerver-Connolly, Laura Dickens, Juliann King, Donna Tarsney, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Rachell Lozano, Michaela Mark, Kathryn Muskovich, J Neff, Kate Pezalla, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Staff Bird, Alison Burke, Cassio Lynm, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Jann Ingmire, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Staff, Mirna Monal, Tim Melroy, Thalia Moss, Tem Harrier, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, Rebecca Haas, Christine Hearne, Irma Lara, Audra Lawlor, Scott Marketing, Matt Herron, Elizabeth Solaro, Geoffrey Flick, Paul Gee Managers, Rick Bell, Michael Mcgraw, Sara Nagy, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, Sean O'donnell, Sean Ohlson, Phil O'leary, Ryan Patella, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Brenda Chandler-Grayer, Scott Curl, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dimitri Christakis, Washington Joffe, Ron Keren, Suzanne Shuey, Benjamin French, Peter Cummings, Samir Shah, Howard Bauchner, Frederick Rivara, Matthew Davis, Ann Arbor, Cherrie Boyer, San Francisco, Robert Bradley, Maria Britto, John Campo, Aaron Carroll, Indiana Frank, Joseph Chaloupka, Mitchell Cohen, Chris Feudtner, Kathleen Janz, Iowa City, Terry Klassen, Joyce Lee, Michigan Michelle, Huckaby Lewis, Maryland Saiman, New York, York Samir, Martha Sola-Visner, Jean-Claude Carel, Shabir Madhi, Ben Marais, Frank Oberklaid, Susan Sawyer, Joan-Carles Surís
Journal: JAMA Pediatrics (2013)
INDICATIONS FOR TRACHEOTOMY IN BULBAR POLIOMYELITIS
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
Authors: Margot Lazow, Christine Fuller, Adam Lane, Mariko DeWire, Pratiti Bandopadhayay, Ute Bartels, Eric Bouffet, Sylvia Cheng, Kenneth J Cohen, Tabitha Cooney, Scott Coven, Hetal Dholaria, Blanca Diez, Kathleen Dorris, Motasem El-Ayadi, Ayman El-Sheikh, Paul Fisher, Mercedes Garcia Lombardi, Robert Greiner, Stewart Goldman, Nicholas Gottardo, Sridharan Gururangan, Jordan Hansford, Tim Hassall, Cynthia Hawkins, Lindsay Kilburn, Carl Koschmann, Sarah Leary, Jie Ma, Jane Minturn, Michelle Monje, Roger Packer, Yvan Samson, Eric S Sandler, Gustavo Sevlever, Christopher Tinkle, Karen Tsui, Lars Wagner, Mohamed Zaghloul, David Ziegler, Brooklyn Chaney, Katie Black, Anthony Asher, Rachid Drissi, Maryam Fouladi, Blaise Jones, James Leach
Journal: Neuro-Oncology (2020)

Abstract INTRODUCTION The role of diagnostic biopsy in diffuse intrinsic pontine glioma (DIPG) remains in question. Distinguishing radiographically between DIPG and other pontine tumors with more favorable prognosis and different therapy is critically important. METHODS Cases submitted to the International DIPG registry with histopathologic data were analyzed. Central imaging review was performed on diagnostic brain MRI (if available) by two neuro-radiologists; all cases with imaging features or histopathology suggestive of alternative diagnoses were re-reviewed. Imaging features suggestive of alternative diagnoses included non-pontine origin, &amp;lt; 50% pontine involvement (without typical DIPG pattern on follow-up), focally exophytic morphology, sharply-defined margins, or marked diffusion restriction throughout. RESULTS Among 294 patients with pathology from biopsy and/or autopsy available, 27 (9%) had histologic diagnoses not consistent with DIPG, most commonly pilocytic astrocytomas (n=11) and embryonal tumors (n=9). Of these 294 patients with biopsy and/or autopsy pathologic data, 163 also had diagnostic MRI available for central neuroimaging review and radiographic comparison. Among 81 patients classified as characteristic of DIPG, 80 (99%) had histopathology consistent with DIPG (diffuse midline glioma, H3K27M-mutant, glioblastoma, anaplastic astrocytoma, diffuse astrocytoma). Among 63 patients classified as likely DIPG, but with unusual imaging features, 59 (94%) had histopathology consistent with DIPG. Nineteen patients had imaging features suggestive of another diagnosis, including 13 with non-pontine tumor origin; the remaining 6 patients all had histopathology not consistent with DIPG (embryonal tumors [n=3, including 1 with medulloblastoma], pilocytic astrocytoma [n=1], and ganglioglioma [n=1]). Association between central imaging review and histopathology was significant (p &amp;lt; 0.001 by the Freeman-Halton Fischer Exact Probability Test). CONCLUSIONS The important role and accuracy of central neuroimaging review in diagnosing or excluding DIPG is demonstrated. In patients with pontine tumors for which DIPG is felt unlikely radiographically, biopsy may be considered to guide diagnosis, prognosis, and treatment.
Physiology
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Marriage.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DISEASE OF INEBRIETY.ITS STUDY FROM THE STANDPOINT OF THE EXPERIENCE OF AMERICAN PHYSICIANS OF EMINENCE WHO HAVE WORKED IN THIS FIELD OF RESEARCH.
Authors: EDWARD C. MANN
Journal: JAMA (1894)

(<i>Continued from page 826</i>.) CONFIRMED INEBRIATES. I shall call the first class confirmed inebriates. I prefer the word, confirmed, to the more common term, habitual, for the reason that one may be in the<i>habit</i>of occasional or frequent intoxication, and yet not be so far established in the habit as to warrant the application of the term in its ordinary sense. How to care for this class, more than any other, is the problem that the civilized world is now endeavoring to solve and in which every household is immediately or remotely concerned. Confirmed inebriates constitute a considerable class of the community; they are as a rule, largely unproductive, and a necessary drain upon the resources of the people. What can be done for or with them? The first thought in this connection involves the idea of custody and restraint and this is always offensive to the intuitive love
THE LONGEVITY OF THE ERYTHROCYTE
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influenza viruses do their best to thwart next winter's vaccine
Authors: C. Marwick
Journal: JAMA (1984)

A new variant of one of the two A-type human influenza viruses has emerged. Sufficiently different from the A-type viruses presently circulating in the United States, it is to be incorporated in next winter's influenza vaccine, a Food and Drug Administration advisory committee has decided. At the same time, the outbreak of avian influenza that has decimated flocks of chickens in Pennsylvania and that also has appeared in New Jersey, Maryland, and Virginia is threatening the supply of fertilized eggs on which flu vaccine manufacturers depend for growing the virus. "We don't anticipate being unable to meet our production goals for flu vaccine next year," said Frank Brandon, PhD, of Parke-Davis, Morris Plains, NJ, a division of the Warner-Lambert Company and one of the three US manufacturers of flu vaccine. "However, eggs are in short supply and this is pushing up the price." How this will affect the cost of
Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.
Authors: Aziz Nazha, Carlos E. Bueso-Ramos, Stefan Faderl, Elihu H. Estey, Susan M. O'Brien, Michael Farnandez, Martin Nguyen, Charles Koller, Emil Freireich, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood (2012)
378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
Authors: A. Sezer, S. Kilickap, M. Gümüş, I. Bondarenko, M. Özgüroğlu, M. Gogishvili, H.M. Turk, İ. Çiçin, D. Bentsion, O. Gladkov, P. Clingan, V. Sriuranpong, N. Rizvi, S. Li, S. Lee, G. Gullo, I. Lowy, P. Rietschel
Journal: Annals of Oncology (2020)
Erratum
Journal: BMJ (1905)

Queries, answers, and communications relating to subjects to which specia I departments ofthe BMTISH MEDICAL JOURNAL are devoted wiU be foundsunder their respective headings.QUERNIES.OLD PRACTITIONER would thank in anticipation any teacher of chemistry who would recommend to him anv book or books which would expound as lucidly as possible the principles of chemistry; one in which illus- trative examples
Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
Authors: Richard D. Carvajal, Jeffrey Alan Sosman, Fernando Quevedo, Mohammed M. Milhem, Anthony Michael Joshua, Ragini Reiney Kudchadkar, Gerald P. Linette, Thomas Gajewski, Jose Lutzky, David H. Lawson, Christopher D. Lao, Patrick J. Flynn, Mark R. Albertini, Takami Sato, Daniel Paucar, Katherine S. Panageas, Mark Andrew Dickson, Jedd D. Wolchok, Paul B. Chapman, Gary K. Schwartz
Journal: Journal of Clinical Oncology (2013)

CRA9003 Background: Gq/11 mutations are early oncogenic events in UM resulting in MAPK pathway activation. We demonstrated decreased viability in UM cell lines harboring Gq/11 mut with sel, a small molecule inhibitor of MEK1/2 (Ambrosini, CCR 2012). Methods: We conducted a 16 center randomized phase II study of hyd-sulfate sel 75 mg BID vs TMZ 150 mg/m 2 daily for 5 days in 28-day cycles (or DTIC 1000 mg/m 2 q21 days) for patients (pts) with metastatic UM with a Q209 Gq/11 mut who have not received prior TMZ/DTIC. The primary endpoint was progression free survival (PFS). Secondary endpoints included overall survival (OS) and response rate (RR). Select pts underwent tumor biopsies at baseline and after 14 (+/- 3 days) of sel. Our statistical plan required ≥80 pts randomized and ≥68 events to detect a PFS hazard ratio of 0.6 (p=0.1). Randomization was stratified by mut (Gq vs G11), M stage and number of prior therapies (tx). Tumor assessment occurred every 4 weeks (wks) for 8 wks and then every 8 wks using RECIST 1.1. Pts receiving TMZ who progressed could receive sel (TMZ→sel). Results: 80 pts were randomized. Sel (n=39): median age 66 (range 32-86), 54% male, 54% G11 mut, median ECOG PS 0 (range 0-1), 97% M1c, median prior tx 0 (range 0-2). TMZ (n=41): median age 60 (range 34-81), 63% male, 58% G11 mut, median ECOG PS 0 (range 0-1), 93% M1c, median prior tx 0 (range 0-2). 11/39 (28%) pts on sel experienced grade (gr) 3 toxicity (tox) manageable with dose modification (5 CPK elevation, 3 LFT elevation, 1 rash, 1 lymphopenia, 1 edema). 1/41 (2%) pt on TMZ experienced gr 3 tox (neutropenia). No gr 4/5 tox occurred. 28 pts on sel underwent paired tumor biopsies with inhibition of pERK and cyclinD1 observed by Western blot at day 14. At interim analysis (9/25/12), 55 pts were evaluable with 45 progression events and 16 deaths. Sel (n=27): median PFS 16 wks (95% CI 8-30.9), RR 11%, median OS 11.8 months (95% CI 4.8-not reached). TMZ (n=28): median PFS 4 wks (95% CI 3.7-15), RR 0%, median OS 4.7 months (95% CI 4.3-14.3). TMZ→sel (n=25): median PFS 8.1 wks (95% CI 7-15), RR 0%. Conclusions: Sel is the first drug to ever show improved clinical activity in UM relative to TMZ. Sustained target inhibition is observed with sel. Final results will be presented. Clinical trial information: NCT01143402.
Antibiotic activity in surgical incisions. The basis of prophylaxis in selected operations
Authors: H. C. Polk
Journal: JAMA (1980)

Perioperative antibiotic administration to produce systemic effects reduces the frequency of operative wound infection in selected procedures. Controlled clinical trials now indicate that cephalothin sodium may not be effective in this role, whereas cephaloridine and cefazolin sodium have been beneficial. Review of estimates of incisional antibiotic concentrations taken during prospective patient studies display patterns compatible with these data. Each drug reaches acceptable incisional concentrations, which are relatively well maintained for cephaloridine and cefazolin; cephalothin disappears from human incisions so rapidly as to provide little wound protection in operations lasting more than one hour. (<i>JAMA</i>244:1353-1354, 1980)
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Authors: Beata Holkova, Edward B. Perkins, Lubomir Sokol, Kristy L. Richards, Samir Parekh, Rebecca Elstrom, Ashraf Z. Badros, Igor Espinoza-Delgado, Michael J. Schell, Amy Kimball, Mary Beth Tombes, Ellen Shrader, Heidi Sankala, Domenico Coppola, Maciej Kmieciak, Daniel Sullivan, John D. Roberts, Steven Grant
Journal: Blood (2011)